Atea Pharmaceuticals (AVIR) Stock Statistics & Valuation Metrics

Atea Pharmaceuticals has a market cap or net worth of $345.68M. The enterprise value is $153.19M.

Market Cap

$345.68M

Enterprise Value

$153.19M

Atea Pharmaceuticals has 80,204,700 shares outstanding. The number of shares has decreased by -2.65% in one year.

Shares Outstanding

80,204,700

Owned by Insiders

11.27%

Owned by Institutions

38.49%

Atea Pharmaceuticals’s return on equity (ROE) is -0.57 and return on invested capital (ROIC) is -63.02%.

Return on Equity (ROE)

-0.57

Return on Assets (ROA)

-0.50

Return on Invested Capital (ROIC)

-63.02%

Return on Capital Employed (ROCE)

-0.66

Revenue Per Employee

0

Profits Per Employee

-2.88M

Employee Count

55

Asset Turnover

0.00

Inventory Turnover

0.00

The current PE Ratio of Atea Pharmaceuticals is -2.26. Atea Pharmaceuticals’s PEG ratio is 0.20.

PE Ratio

-2.26

PS Ratio

0.00

PB Ratio

2.01

Price to FCF

-2.33

Price to Operating Cash Flow

-2.33

PEG Ratio

0.20

In the last 12 months, Atea Pharmaceuticals had revenue of 0 and earned -158.35M in profits. Earnings per share was -1.94.

Revenue

0

Gross Profit

0

Operating Income

-180.89M

Pretax Income

-164.51M

Net Income

-158.35M

EBITDA

-164.09M

Earnings Per Share (EPS)

-1.94

In the last 12 months, operating cash flow was -152.07M and capital expenditures 0, giving a free cash flow of -152.07M billion.

Operating Cash Flow

-152.07M

Free Cash Flow

-152.07M

Free Cash Flow per Share

-1.90

Atea Pharmaceuticals pays an annual dividend of ―, resulting in a dividend yield of ―

Dividend Per Share

―

Dividend Yield

―

Payout Ratio

N/A

Free Cash Flow Yield

-42.99%

Earnings Yield

-46.82%

Beta

0.60

52-Week Price Change

32.62%

50-Day Moving Average

4.93

200-Day Moving Average

4.97

Relative Strength Index (RSI)

43.97

Average Volume (3m)

284.17K

Atea Pharmaceuticals upcoming earnings date is Mar 02, 2027, TBA (Not Confirmed).

Last Earnings Date

Nov 09, 2026

Next Earnings Date

Mar 02, 2027

Ex-Dividend Date

―

Atea Pharmaceuticals as a current ratio of 7.82, with Debt / Equity ratio of 0.31%

Current Ratio

7.82

Quick Ratio

7.82

Debt to Market Cap

0.00

Net Debt to EBITDA

0.58

Interest Coverage Ratio

0.00

In the past 12 months, Atea Pharmaceuticals has paid -6.16M in taxes.

Income Tax

-6.16M

Effective Tax Rate

0.04

Atea Pharmaceuticals EV to EBITDA ratio is -1.62, with an EV/FCF ratio of -1.83.

EV to Sales

0.00

EV to EBITDA

-1.62

EV to Free Cash Flow

-1.83

EV to Operating Cash Flow

-1.83

Atea Pharmaceuticals has $219.47M in cash and marketable securities with $424.00K in debt, giving a net cash position of $219.04M billion.

Cash & Marketable Securities

$219.47M

Total Debt

$424.00K

Net Cash

$219.04M

Net Cash Per Share

$2.73

Tangible Book Value Per Share

$2.55

Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.

Gross Margin

0.00%

Operating Margin

0.00%

Pretax Margin

0.00%

Net Profit Margin

0.00%

EBITDA Margin

0.00%

EBIT Margin

0.00%

The average price target for Atea Pharmaceuticals is $7.00, which is 11.43% higher than the current price. The consensus rating is Moderate Buy

Price Target

$7.00

Price Target Upside

62.41% Upside

Analyst Consensus

Moderate Buy

Analyst Count

2

Revenue Growth Forecast

―

EPS Growth Forecast

-29.71%

Smart Score

6

AI Score

53